Introduction
Ghrelin was discovered through its ability to activate the type 1a growth hormone secretagogue receptor (GHS-R) and stimulate growth hormone release in vivo (Smith et al., 2005; van der Lely et al., 2004 ). An evolutionarily conserved feature of ghrelin is the acylation of its third residue, usually with n-octanoic and, less commonly, with n-decanoic acid (Hosoda et al., 2003) . Kojima et al (Kojima et al., 1999) were the first to describe the requirement that ghrelin be acylated on its third serine residue for activation of the GHS-R in the nanomolar range, with an EC 50 for increased [Ca 2+ ] i of 2.5 x 10 -9 M. In the circulation, ghrelin also occurs as a unacylated isoform (UAG) at 10-50 times the concentration of acylated ghrelin (Kojima and Kangawa, 2005 , and our unpublished observations).
Of great interest to us has been the finding that in humans co-administration of UAG can antagonize the metabolic effects of ghrelin in vivo. Ghrelin administration causes hyperglycemia, hypoinsulinemia, increased circulating free fatty acids and worsening insulin sensitivity, but these effects are reversed or prevented by co-administration with UAG Gauna et al., 2004) . These effects seem to be specific to ghrelin's metabolic activity since UAG has no impact on GH, PRL or ACTH secretion . This suggested a direct action on the endocrine pancreas, and perhaps on hepatic glucose production. In relation to these in vivo findings, we have shown that UAG A c c e p t e d M a n u s c r i p t 4 not only suppresses glucose output, but also blocks ghrelin induced glucose release by primary hepatocytes (Gauna et al., 2005) . In support of these findings, a recent report demonstrated the antagonistic effect in fish where ghrelin's orexigenic effects were blocked by administration of UAG. Furthermore, this effect appears to occur both centrally and peripherally (Matsuda et al., 2006) .
There are now many reports of direct biological activity of UAG in vitro that suggest a receptor mediated cellular response, perhaps via a specific receptor that is not GHS-R (Baldanzi et al., 2002; Cassoni et al., 2004; Chen et al., 2005; Gauna et al., 2006; Muccioli et al., 2004; Nanzer et al., 2004; Thompson et al., 2003; Toshinai et al., 2006) . Despite these findings, the current consensus appears to be that UAG is inactive as an agonist of the GHS-R. However, the possibility remains that UAG is somehow able to block the ghrelin response by antagonizing the GHS-R. Therefore, we have explored in more detail, in a defined in vitro system, the ability of UAG to antagonize activation of the GHS-R by ghrelin, the potency of UAG at the GHS-R, and the effects of GHS-R antagonists.
Materials and Methods

Peptides
Human UAG was obtained from NeoMPS (Strasbourg, France) and Thera 
Aequoscreen assay for ghrelin and UAG activity
Aequoscreen cells were kindly provided by Euroscreen s.a.
(Gosselies, Belgium). These cells (CHO-A5) are stably transfected with a pIRES-puro (Clontech, Mountain View, CA) construct containing mitochondrially targeted apoaequorin which allows luminometric determination of [Ca] i . An identical cell line was also provided that had also been stably transfected with a human GHSR1a expression construct with a Neo cassette (CHO-A5-GHSR). These cell lines were maintained in HAM F12 containing 10% fetal calf serum, 2.5 µg/mL amphotericin, 100 IU/mL penicillin, 100 µg/mL streptomycin, 5 µg/mL puromycin.
The GHS-R expressing cells were maintained in the same medium but with the addition of 400 µg/mL G418. On the day of the assay the cells were resuspended in BSA assay buffer (DMEM/HAM's F12, with HEPES, without phenol red, 0.1% BSA, 2.5 µg/mL amphotericin, 100 IU/mL penicillin, 100 µg/mL streptomycin) at 5x10 6 cells/ml, and then coelenterazine h (Sigma, St Louis, MO) was added to a final concentration of 5 µM. Cells were incubated at room temperature for 4 h and kept in suspension by gentle rotation. Cells were then diluted with BSA assay buffer to 5x10 5 cells/ml, and 100 µL was injected into wells of a black 96-well plate containing 100 µL of various concentrations and combinations of ghrelin, UAG and other peptides. Luminescence was integrated for 15 s using a Victor2 1420 multilabel counter (Perkin-Elmer, Wellesley, MA, USA), a short enough time that it is very unlikely that modification of the UAG could occur during the assay.
After collection of data, the residual response of the cells was measured by permeabilizing their membranes with 100 µL of 1% Triton X-100. Data were 
Radioligand binding studies
Membranes were prepared from CHO-A5-GHSR cells using a protocol from Euroscreen. Briefly, cells at 80% confluence in monolayer culture in 75 cm2 flasks, were scraped into PBS, then pelleted at 1500xg for 3 min. The cell pellet was then resuspended in buffer A (15 mM Tris-HCl (pH7.4), 2 mM MgCl 2 , 0.3 mM EDTA, 1 mM EGTA) at 4°C and homogenized in a glass/teflon homogenizer.
The crude membrane fraction was collected by two consecutive centrifugation steps at 40,000 x g for 25 min separated by a washing step in buffer A. Non-linear regression analysis was performed using Graphpad Prism.
Results
The main reason for examining UAG modulation of GHS-R activity was to elucidate a mechanism for our finding that this peptide could antagonize the effects of ghrelin on hepatocyte glucose production in vitro (Gauna et al., 2005) .
Therefore, the first experiment that we ran was designed to determine if UAG had any antagonistic activity in an in vitro system where we could examine its rapid effects directly. We have used Aequoscreen cells transfected with the human GHS-R (CHO-A5-GHSR) for this purpose, where the induction of [Ca 2+ ] i
by exposure of the cells to ghrelin can be accurately and rapidly assessed by measuring aequorin luminescence. CHO-A5-GHSR cells are sensitive to ghrelin treatment, responding consistently and robustly with an EC 50 of ~2 nM (Fig.1A) .
In initial experiments we treated the cells with 2.5 nM or 5 nM ghrelin (generating approximately 80 and 93% of their maximum luminescence response) together with increasing concentrations of UAG ranging from 10 -10 to 10 -5 M (Fig. 1A) . We found that over this dose range UAG does not antagonise ghrelin's action on the GHS-R. In fact, under conditions of sub-maximal stimulation with 2.5 nM ghrelin, UAG in the low micromolar range was able to further stimulate the cells towards their maximal fractional response (in this case, 93%).
The possibility remained that the CHO-A5 cells themselves contained a receptor that was responsive to UAG, and that the response we were measuring was not derived from activation of the GHS-R but from another receptor. Therefore, we tested the response to UAG and ghrelin in Aequoscreen cells that had not been transfected with the GHS-R. Dose response curves for UAG (10 -8 M to 10 -5 M) and ghrelin (10 -10 M to 10 -7 M) caused no luminescent response from these cells (Fig. 1A) , whereas combined treatment with 0.5 µM PMA and 100 nM A23187 elicited a maximal fractional response of 0.98 ±0.003 (n=4). These findings confirm that the response we have measured for UAG is not mediated by an alternative receptor system in CHO-A5 cells. There was also the possibility that UAG was having a non-specific effect on receptor activation in the micromolar range. To test this we ran dose response curves for three other peptides of similar size but unrelated amino acid sequence (somatostatin28, obestatin and glucagon) at between 5x10 -11 and 10 -5 M. None of these peptides generated a signal at any of the concentrations tested (Fig. 1B) .
UAG may antagonise ghrelin's action at concentrations other than ghrelin's EC 90 .
To test this possibility, we examined the response of the aequoscreen cells to UAG in the presence of ghrelin at concentrations that spanned its dose response curve. UAG had no antagonistic effect on any of these concentrations of ghrelin (Fig. 1C) , and the results are fully consistent with UAG acting agonistically on the GHSR in the 10 -7 to low 10 -6 M concentration range.
We also constructed dose response curves using two different sources of the peptide (NeoMPS and Thera Technologies). These experiments showed that UAG is a full agonist of the GHS-R with EC 50 values of 1.6 µM (n=4, R (Fig. 2B ). Ghrelin demonstrated a typical displacement curve using the same membrane preparations ( Fig. 2B ; IC 50 , 7 nM).
As additional evidence that UAG was activating the GHS-R, we tested the ability of two GHS-R antagonists to block its effect. BIM28163 is an analog of full-length ghrelin (Halem et al., 2005) , whereas [D-Lys 3 ]GHRP-6 is an antagonistic analog of the hexapeptide growth hormone secretagogue GHRP-6 (Cheng et al., 1989) .
Both have been demonstrated to have antagonistic activity in vitro and in vivo (Cheng et al., 1989; Halem et al., 2005 ]GHRP-6; 238 nM and 700 nM, respectively). The potencies of these antagonists was similar to those found against ghrelin using the same in vitro system (Fig. 3B; BIM28163 and [D-Lys 3 ]GHRP-6; 240 nM and 1.98 µM, respectively). These data suggest that UAG activates the GHS-R with a similar mechanism of action.
Discussion
Overall, our observations in a cell line in which we can measure the effects of peptides exclusively on GHSR activation suggest that UAG can reinforce the activity of ghrelin, depending on effective concentrations. However in other in vitro models, and in vivo, the situation appears to be more complex. Previous studies show that UAG can displace radiolabelled ghrelin from membrane extracts of cell-lines that lack expression of GHS-R1a mRNA (eg. Cassoni et al., 2001; Muccioli et al., 2004) , and that UAG can antagonise ghrelin induced glucose release in hepatocytes (Gauna et al., 2005 ) that probably do not express GHS-R1a. These studies present the argument that there is a separate UAG receptor that is involved in modulating the metabolic effects of ghrelin in vivo, for example on glucose homeostasis Gauna et al., 2004) . In these instances, UAG could modulate the metabolic effects of ghrelin directly in the liver or pancreas directly on a receptor that is shared by ghrelin and UAG, or indirectly via a UAG-specific receptor. It is likely that a direct antagonistic effect of UAG on ghrelin activity at the GHSR is ruled out by our findings, strengthening the argument for an alternate receptor that is involved in the antagonistic effects of UAG.
However, we also demonstrate that UAG is capable of activating the GHS-R in the high nanomolar to low micromolar range in the Aequoscreen in vitro system.
These are lower concentrations than previously determined, suggesting that UAG could activate GHS-R in other cellular systems, perhaps even in vivo. An important issue is whether local concentrations of UAG ever reach the levels needed for agonistic action on GHS-R. Hormone concentrations can reach levels in tissues that are not attained in the circulation, through local production.
Examples of this include interleukin-6, and the peptide hormones angiotensin-I and angiotensin-II which have been demonstrated to attain tissue concentrations 100-fold higher than circulating levels (Sopasakis et al., 2004; van Kats et al., 2001) . It has recently been demonstrated that UAG concentrations are in the nanomolar range in the pancreatic (splenic) vein resulting from high levels of local production in the pancreas (Dezaki et al., 2006) . If, like the similarly sized angiotensins, pancreatic tissue levels of UAG were 100-fold greater than in the circulation, then this would bring local concentrations into the range required to activate the GHS-R. Ghrelin appears to be synthesized in numerous tissues (Gnanapavan et al., 2002) , in each of which local concentrations of both acylated and UAG may reach concentrations higher than those in the blood. Additionally, high local concentrations of UAG could also occur in certain experimental conditions, such as at the site of infusion of the peptide.
Bednarek et al (Bednarek et al., 2000) examined the requirement for a bulky hydrophobic group in the side chain of the Ser 3 residue of ghrelin for its ability to activate GHS-R1a in a similar aequorin reporter system. This study found that human UAG activated the GHSR to 40% of maximal values at 10 µM. A similar structure-function study of rat ghrelin that measured [Ca 2+ ] i mobilization using Fura2 has been described by Matsumoto et al (Matsumoto et al., 2001) , with UAG activating the GHSR with an EC 50 of 3.5 µM. Although these studies hinted at the activity of the des-octanoylated form of the peptide, they did not directly address the possibility of a functional antagonistic effect of UAG on this receptor.
We find that human UAG activates the human GHSR with similar or greater potency to that of rat UAG, and that its mechanism of action is similar to that of ghrelin since GHSR antagonists block its action. Our data suggest UAG may act on the GHSR in a potentially physiological range of concentrations. At the very least, our findings illustrate that peptide concentration must be carefully considered in experiments where local concentrations of UAG may reach the low micromolar range in vivo, or in in vitro experiments.
In conclusion, we find in a defined in vitro system that UAG cannot functionally antagonize the action of ghrelin on the GHS-R. This suggests that the apparent antagonistic activity of UAG is mediated by an indirect mechanism, perhaps involving a specific UAG ghrelin receptor. UAG is a full agonist of the GHS-R, with activity in the high nanomolar range. The ability of UAG to interact with the GHS-R makes it necessary to interpret GHS-R independent activity of this 
